Feature | EP Lab | May 15, 2015

Remote Monitoring Recommended by HRS to Become Standard of Care

International panel of experts advocates for continuous monitoring supplemented with annual in-person appointments

HRS, remote monitoring, RM, standard of care, CIEDs

May 15, 2015 — A new expert consensus statement by the Heart Rhythm Society (HRS) recommends remote monitoring (RM) become standard of care for patients with cardiovascular implantable electronic devices (CIEDs). The HRS Expert Consensus Statement on Remote Interrogation and Monitoring for Cardiovascular Electronic Implantable Devices was written by an international group of experts and published online in HeartRhythm Journal, the official journal of HRS. This new approach presents a new paradigm for managing patients with CIEDs and will be presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th Annual Scientific Sessions.

Over the past decade, novel technologies have created the ability for devices to monitor their own function, record arrhythmias and communicate this information to healthcare providers without participation of the patient. Enrollment in RM has become accessible to all patients and allows doctors to monitor a patient’s device between follow-up visits and alerts them to any issues via wireless technology.

The new expert consensus statement builds upon the 2008 HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs), and reinforces the need for consistent follow-up and outlines the limitations of in-person-only follow-up. The writing group focuses on the organizational change required to most effectively implement RM by replacing the occasional, routine appointment to a system of nearly continuous monitoring, making it more convenient and efficient for the patient and healthcare provider. Recommendations also include that the patient have an in-person evaluation at the physician’s office in response to alert notifications communicated by RM.

“We’ve seen firsthand how the constant and continuous communication between the patient’s device and the healthcare provider is improving the quality and efficiency of care. There are proven advantages for the patient and we outline a specific strategy on how remote monitoring can benefit both patients and providers,” said task force chair and lead author of the statement, David Slotwiner, M.D.,FHRS,  Hofstra School of Medicine, North Shore-Long Island Jewish Health in New Hyde Park, New York. “We hope that this type of wireless, remote monitoring that provides real-time insights to the patient’s healthcare team can become a model for managing other chronic conditions.”

Key recommendations within the expert consensus statement include the following:

  • Remote monitoring should be combined with at least an annual in-person evaluation and all patients with CIEDs should be offered remote monitoring as part of the standard follow-up management strategy;
  • Before implementing RM, it is recommended that each patient be educated about the nature of RM, responsibilities and expectations, potential benefits, limitations and an explanation of how RM information may be used;
  • All CIEDs be checked through direct patient contact 2-12 weeks after being implanted; and
  • Have specific policies in place to govern program operations, roles and responsibilities of those involved and the expected timelines for service provision.

 

The expert consensus statement was developed in collaboration with the American College of Cardiology (ACC), Pediatric & Congenital Electrophysiology Society (PACES), the American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), the European Heart Rhythm Association (EHRA) and Latin American Society of Cardiac Pacing and Electrophysiology (Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología, SOLAECE).   

For more information: www.hrsonline.org

Related Content

HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater ri
he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

News | EP Lab | May 20, 2020
May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of...
Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
News | EP Lab | May 19, 2020
May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), an
HRS presentations included BlueSync Evaluation study for Medtronic MyCareLink Heart mobile app and Micra TPS CED Study
News | EP Lab | May 14, 2020
May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia in the NODE-301 trial presented at Heart Rhythm 2020. #heartrhythm2020 #HRS2020
News | EP Lab | May 13, 2020
May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating pati
Medtronic Cobalt and Crome ICD
News | EP Lab | May 12, 2020
May 12, 2020 — Medtronic has received FDA approval for its Cobalt and Crome implantable cardioverter-defibrillators (
The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time. FDA clears, approved, the HeartLight X3 Laser Ablation System to Treat Atrial Fibrillation.

The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time.

News | EP Lab | May 12, 2020
May 12, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the next-generation CardioFocus Inc.
EP lab photo from Philips Healthcare
News | EP Lab | April 30, 2020
May 1, 2020 — The Heart Rhythm Society (HRS) has created a COVID-19 Task Force to make recommendations related to edu
The European Heart Rhythm Association (EHRA) electrophysiology (EP) annual meeting cancelled due to coronavirus. #COVID19 #coronavirus #2019nCoV
Feature | EP Lab | March 10, 2020 | Dave Fornell, Editor
March 10, 2020 — Novel coronavirus (...
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical SuperMap, an addition to its AcQMap 3-D imaging and mapping system used to guide electrophysiology (EP) catheter ablation procedures. Adding the SuperMap mode to the AcQMap system enables users to visualize any atrial rhythm in less than three minutes. Rapidly mapping and re-mapping the whole heart chamber facilitates a new procedural workflow in EP ablation, making it practical to execute an iterative "map, ablate, re-map" approach.
News | EP Lab | March 05, 2020
March 5, 2020 — The U.S.